Background: The glutathione thymidine repeats [(GT) n ] of the heme oxygenase (HO)-1 gene promoter have been shown to be correlated with the incidence of coronary artery disease (CAD), patients with shorter repeats being less likely to have CAD. In this study, we investigated whether (GT) n repeats in the HO-1 promoter were related to a quantitative angiographic severity of CAD. Methods: The allele frequency of the HO-1 gene promoter (GT) n repeats was examined in CAD patients with de novo lesions (n ¼ 328). Patients' baseline coronary severity was quantified using the Jeopardy scoring system. Results: The allele frequency of GT repeats in the HO-1 gene promoter had bimodal peaks at (GT) 23 and (GT) 30. Therefore, we defined allele classes as follows: S allele (<23 repeats), M allele (23e29 repeats), and L allele (!30 repeats). The group with severe CAD (Jeopardy score !8) had a significantly lower frequency of the S allele (3.7% vs. 8.9%; p ¼ 0.042) than the group with moderate CAD (Jeopardy score <8). None of the patient with the highest score of 12 (n ¼ 17) carried the class S allele. In a multivariate binary logistic analysis, being a carrier of shorter GT repeats was a significant negative predictor (odds ratio 0.393; p ¼ 0.024) of a higher Jeopardy score grade of CAD. Conclusion: Our study showed that shorter (GT) n repeat in the HO-1 gene promoter were associated with a lower Jeopardy severity score in patients with significant CAD.
Introduction
Heme oxygenase (HO)-1 is a rate-limiting enzyme for degrading heme into carbon monoxide, free iron, and biliverdin. 1 Carbon monoxide, like nitric oxide, is a potent vasodilator, and biliverdin and its end-product bilirubin are antioxidants in vascular cells. 1, 2 Moreover, HO-1 also promotes angiogenesis and inhibits vascular smooth muscle cell proliferation. 3, 4 The number of glutathione thymidine (GT) dinucleotide repeats in the HO-1 gene promoter regulates gene transcription activity. 5, 6 Longer GT repeats in the HO-1 gene promoter have been reported to be associated with susceptibility to coronary artery disease (CAD) in diabetic patients, 5 an increased risk of ischemic stroke, 7 an increased incidence of type 2 diabetes mellitus, 8 and a higher restenosis rate after percutaneous coronary intervention (PCI). 9 By contrast, shorter GT repeats have been shown to be correlated with higher HO-1 promoter activity in vitro, 5 a lower incidence of CAD in a population with coronary risk factors, 10 fewer coronary events in patients with peripheral artery disease, 11 and a lower restenosis rate after PCI. 6 However, some studies have not supported findings that (GT) n repeats in the HO-1 promoter are related to susceptibility to CAD 12 or restenosis after PCI. 13 Several scoring systems have been developed to quantify the angiographic severity of coronary atherosclerosis and have been correlated with CAD outcomes.
14e17 Among them, the Jeopardy score offers a simple and precise method for estimating the myocardium at risk and has been shown to correlate with long-term survival rates in patients with CAD, 14 the outcomes of cardiogenic shock after myocardial infarction, 18 and in-hospital cardiac mortality after acute vessel closure in PCI. 19 To further explore the link between HO-1 promoter (GT) n repeats and the quantitative angiographic severity of CAD, we conducted a retrospective analysis of patients who had undergone cardiac catheterization.
Methods

Study population
A Windows 2000-based cardiac catheterization report databank has recently been established in our institute, using hospital information system data stored in the mainframe; this contains all of the hospital's angiographic report data for the past 15 years. In addition, a serum and buffy coat databank for all patients who had undergone different types of cardiac catheterization and who were willing to donate their blood samples for academic use was established in March 1999. All study participants gave their informed consent prior to the blood sampling.
The current study is a substudy of an original protocol that investigated the association between inflammation-linked markers and postcoronary intervention restenosis. 20, 21 During the study period from March 1999 to January 2004, a total of 11,200 coronary angiogram procedures were undertaken in our institute's catheterization laboratories. Among them, 1566 Han Chinese patients received more than one procedure for various reasons. Patients who had an acute infection or systemic inflammation disorders such as connective tissue disease were also excluded from the study. Those who had a history of coronary revascularization prior to the first (index) coronary angiogram in the study period were also excluded, as were patients who had had severe heart failure, surgery, advanced renal insufficiency, or cerebrovascular events in the 2 months prior to the index coronary angiograms.
The database was queried for consecutive patients with stable angina who had angiographic follow-ups after PCI for de novo native lesions. Patients who met the catheterization inclusion criteria (coronary lesions with stenosis of !75% of the vessel diameter that were associated with objective evidence of ischemia) were subsequently checked in the buffy coat databank for preprocedural blood samples taken at the index PCI. The relevant clinical demographic data were retrieved from the database and completed by thoroughly reviewing the medical chart records. Because this is a substudy of "restenosis vs. non-restenosis" after PCI, all the cases were CAD with de novo lesions that underwent a coronary angiogram at least twice and donated buffy coat samples for leukocyte genomic DNA extraction within the study period (n ¼ 328). Consequently, potential case selection bias could not be avoided. The study protocol was approved by the institutional review board for human research of Taichung Veterans General Hospital (Taichung, Taiwan).
Jeopardy score and angiographic definition
Angiographic measurements were made on a viewing workstation with software for the quantitative analysis of angiograms (Philips Inturis Suite R2.2; Philips Medical Systems, Eindhoven, The Netherlands). The Jeopardy scoring system was designed to estimate the myocardium at risk or in jeopardy. 14 The coronary arteries were divided into six major segments: left anterior descending artery, major diagonal branch, major septal branch, left circumflex artery, major obtuse marginal branch, and right coronary artery. Two points were given to each segment with >75% stenosis, and 2 points were added to the total score for each vessel that was distal to a 75% stenosis.
14 Therefore all study patients with significant coronary stenosis could be graded with a quantitative Jeopardy score (range 2e12) for the severity of their coronary angiographic results.
Definition of conventional risk factors for atherosclerosis
Patients with hypertension were identified as either: (1) those with a systolic blood pressure over 140 mmHg or a diastolic pressure over 90 mmHg after multiple measurements in a sitting position at rest; or (2) patients already taking antihypertensive medication. Patients with diabetes mellitus were defined as: (1) those with a fasting blood sugar level over 126 mg/dL on two occasions; or (2) patients already taking oral antidiabetic agents or insulin injections. Hypercholesterolemia was defined as: (1) a level of total cholesterol over 200 mg/dL; or (2) a low-density lipoprotein cholesterol (LDL-C) level over 130 mg/dL at their index baseline admission or on other traceable past records prior to the use of an HMGCoA reductase inhibitor. 0 -GCGGAACAGCTGATGCCCACTTT CTGGCCG-3 0 , according to the published procedure. The PCR products were mixed together with a GenoType TAMRA DNA ladder (size range 50e500 bp; Gibco-BRL, Grand Island, NY) and analyzed with an automated DNA sequencer (ABI Prism 377, Grand Island, NY). The size of each (GT) n repeat was calculated using GeneScan analysis software (PE Applied Biosystems, Grand Island, NY). To further confirm the sizes of the (GT) n repeats, some of the PCR products were subcloned into a pCRTMII vector (Invitrogen, Grand Island, NY), and the purified plasmid DNAs were subjected to sequence analysis.
Statistical analysis
Continuous variables are expressed as mean AE standard deviation, and categorical data as percentages. Differences in continuous variables between groups were assessed by the independent t test or ManneWhitney U test as appropriate.
Categorical variables were compared by Chi-square test with Yate's correction or Fisher's exact test. Multivariate binary logistic regression analysis was used to test independent predictors for a higher Jeopardy score (!8) in patients with significant CAD. A two-tailed p value <0.05 was considered statistically significant. The SPSS 12.1 statistical software package (SPSS Inc., Chicago, IL, USA) was used for all calculations.
Results
Baseline demographic data
A total of 328 patients with significant coronary artery stenosis were enrolled for analysis. The patients were divided into two groups: moderate CAD (Jeopardy score <8, n ¼ 220) or severe CAD (Jeopardy score !8, n ¼ 108). Baseline demographic data, including atherosclerotic risk factors, were similar between the two groups except that the patients in the group with severe CAD were significantly older ( Table 1) . 
Distribution of HO-1 gene promoter genotypes in coronary artery disease patients with Jeopardy scoregraded angiographic severity
The atherosclerotic severities of patients with CAD were graded according to their Jeopardy score ( Table 2 ). The allele frequency of the GT repeat in the HO-1 gene promoter had bimodal peaks at (GT) 23 and (GT) 30 ; therefore, we defined allele classes as follows: class S allele (<23 GT repeats), class M allele (23e29 GT repeats), and class L allele (!30 GT repeats) (Fig. 1A) . The distribution of the six genotypes (SS, SM, SL, MM, ML, and LL) was asymmetric among the CAD patients with different Jeopardy score-graded (range 2e12) severities ( p ¼ 0.024) ( Table 2 ). In the group (n ¼ 17) with the highest severity score (12) , none of the patients carried the class S allele ( Table 2 ).
Carriers of the shorter (GT) n repeat (<23 repeats) allele in the HO-1 gene promoter versus non-carriers with moderate or severe coronary atherosclerosis
The group with moderate CAD (Jeopardy score <8) had more carriers of the class S allele (16.8% vs. 7.4%, p¼0.031) than the group with severe CAD (Jeopardy score !8). The odds ratio for carriers of the class S allele with severe CAD (Jeopardy score !8) was 0.396 (95% confidence interval 0.177e0.882; p ¼ 0.031). In terms of distribution of allele frequency, the group with severe CAD had a significantly lower frequency of the class S allele (3.7 % vs. 8.9%; p ¼ 0.042) than the group with moderate CAD (Table 3 , Fig. 1B and C) .
The average (GT) n repeat number of the HO-1 gene promoter in moderate versus severe coronary atherosclerosis
Moreover, if we assumed a codominant (additive) trait model for the HO-1 gene promoter and calculated an average (GT) n repeat number for each patient, the group with severe CAD (Jeopardy score !8) had a significantly longer average (GT) n (27.8 AE 3.2 vs. 27.0 AE 3.1; p ¼ 0.041) than the group with moderate CAD (Jeopardy score <8).
3.5.
Multivariate binary logistic regression analysis of independent predictors for a higher Jeopardy score in patients with significant coronary artery stenosis
In a multivariate binary logistic regression model with adjustment for conventional risk factors, including hypertension, diabetes mellitus, hypercholesterolemia, and gender, being a carrier of shorter GT repeats was a significant negative predictor (odds ratio 0.393; p ¼ 0.024) of severe CAD (Jeopardy score !8) (Table 4) . By contrast, age was a positive predictor (odds ratio 1.031; p ¼ 0.017) of severe CAD (Jeopardy score !8) (Table 4 ).
Discussion
Carriers of the shorter (GT) n repeats in the HO-1 gene promoter have been shown to have a lower incidence of CAD in the general population with coronary risk factors. 10 However, no study has provided conclusive evidence that the HO-1 gene promoter (GT) n repeat microsatellite polymorphism could be associated with a quantitative angiographic coronary severity. In our study, we found that carriage of shorter (GT) n repeats in the HO-1 gene promoter was associated with a lower angiographic severity in patients with significant coronary artery stenosis.
Age is an important risk factor for coronary atherosclerosis. 24 Patients in the group with severe CAD were significantly older than those in the group with moderate CAD in this study (Table 1 ). However, after adjusting for age and other conventional risk factors for coronary atherosclerosis, carriage of shorter (GT) n repeats (the class S allele) in the HO-1 gene promoter remained a significant negative predictor for a higher Jeopardy score-graded severity of coronary atherosclerosis (Table 4) .
Induction of HO-1 in vascular endothelial cells and smooth muscle cells by proatherogenic agents such as oxidized LDL-C, hypoxia, and proinflammatory cytokines could provide a secondary line of antioxidant defense and maintain vessel patency through the generation of carbon monoxide.
25e28 The HO-1 promoter and its transcriptional activity are regulated by multiple insults, transcription factors, and their response elements. 26 Patients with coronary atherosclerosis usually manifest a status of higher oxidative stress that has induced the HO-1 expression. 26, 29 The (GT) n repeat polymorphism of the HO-1 gene promoter was one of the genetic factors that determined its transcription in patients with CAD.
Previous in vitro studies have revealed that shorter (GT) n repeats in the HO-1 gene promoter were associated with higher transcriptional activity. 5 Carriers of shorter (GT) n repeats in the HO-1 gene promoter had a lower incidence of CAD in a population with coronary risk factors. 10 The above findings may imply that a higher transcription of the HO-1 gene provides protection against atherosclerosis. By contrast, some studies have indicated that HO-1 protein expression was higher in complex or high-grade stenotic coronary lesions or in the coronary arteries of diabetic individuals. 30 Morsi et al demonstrated that HO-1 expression and activity in endothelial cells were only present in advanced atherosclerosis but not in healthy controls. 31 Moreover, Chen et al reported that there was higher HO-1 protein expression in the peripheral leukocytes of patients with CAD than in healthy controls, 32 patients with acute myocardial infarction showing the highest expression. 33 In addition, Idriss et al reported the presence of a secretory form of HO-1 protein in plasma whose concentration was highest in acute coronary syndrome, followed by stable CAD, with healthy controls having the lowest concentration of secretory HO-1.
34
These studies on increased HO-1 expression and activity in advanced atherosclerosis increase the controversy over whether HO-1 itself could protect against atherosclerosis or just serve as a post hoc defense against disease progression. We postulated that a higher expression of HO-1 protein was an adaptation and adjustment to overcome the higher oxidative stress and acted as a promoter of angiogenesis in established and advanced CAD. However, a shorter (GT) n repeat in the HO-1 gene promoter still could provide a background genetic protection against atherosclerosis.
There are two major limitations to our study. First, we did not have HO-1 protein expression data for plasma, peripheral leukocytes, or coronary tissues to document the association between the HO-1 promoter microsatellite polymorphisms and actual protein expression. Second, we did not have long-term Table 4 Multivariate binary logistic regression analysis of independent predictors for a higher Jeopardy severity score (!8) in patients with significant coronary artery stenosis (n ¼ 328). follow-up data on mortality rates or major adverse cardiac event rates to link this HO-1 gene promoter polymorphism to cardiovascular outcomes.
In conclusion, our study showed that carriage of shorter GT repeats in the HO-1 gene promoter was associated with a lower Jeopardy severity score in patients with significant coronary artery stenosis.
inflammatory cells from patients with coronary heart disease. 
